Operating a healthcare facility necessitates acquiring costly medical equipment—an expense that is manageable for some, but unattainable for others. Those who fall into the latter category do have one option, however: leasing their devices.
In the past, the FDA has occasionally waded into the territory of medical device service, refurbishment, repair, reconditioning, and modification. The FDA’s new foray into this arena comes in the form of an open-ended request for comments titled “Refurbishing, Reconditioning, Rebuilding, Remarketing, Remanufacturing, and Servicing of Medical Devices Performed by Third-party Entities and Original Equipment Manufacturers.”
According to a new report published by Markets and Markets, the medical device contract manufacturing market is expected to reach $91.3 billion by 2024, up from an estimated $55 billion in 2019, at a CAGR of 10.6%.
Many healthcare organizations don’t have an effective process for managing equipment dispositions, says Accruent’s Alan Gresch. So, what’s the solution? Create comprehensive plans based around a centralized model, which will provide savings and revenue.
Since William Hyman published his report on the Food and Drug Administration's call for comments regarding repair and refurbishment of medical equipment by OEMs and third parties, 24x7 readers have had a lot to say.
Rising demand for medical devices, coupled with regulatory changes in Europe and other countries around the globe fueling demand for quality assurance and regulatory affairs services, are among the anticipated drivers of the projected market growth.
Digital health company LindaCare is collaborating with Philips to combine LindaCare’s OnePulse cloud-based solution for the remote monitoring of patients with cardiac implantable electronic devices with the Philips IntelliSpace Cardiovascular informatics platform.